Verona Pharma PLC ADR (VRNA) Stock
VRNA is no longer traded. Verona Pharma PLC ADR was acquired by Merck (MRK) on October 7, 2025.
Each VRNA share was exchanged for $107.00 per American Depositary Share in cash. Prices on this page are historical; the last trade was October 6, 2025 at $106.91.
See Merck (MRK) stock →Verona Pharma PLC ADR stock price history
VRNA final trading statistics
- Final close
- $106.91
- Final trading day
- Oct 6, 2025
- Market cap at delisting
- $9.09B
- Shares outstanding
- 84.98M
- Final 52-week range
- $31.09 – $106.93
- Avg. volume (final 3 mo.)
- 3,558,507
- All-time high (split-adj.)
- $106.91 · Oct 2025
- All-time low (split-adj.)
- $2.16 · Mar 2020
- Return since IPO
- +691.9%
- Beta
- 0.05
- Book value / share
- $3.24
- Price / book
- 33.04
Verona Pharma PLC ADR annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $33.77M | -$138.5M | -$1.81 |
| FY2023 | $458.0K | -$42.6M | -$0.47 |
| FY2022 | $378.9K | -$56.8M | -$1.11 |
| FY2021 | $29.58M | -$41.1M | -$0.97 |
| FY2020 | $2.4K | -$47.6M | -$2.47 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
Verona Pharma PLC ADR stock FAQ
What happened to Verona Pharma PLC ADR stock?
Verona Pharma PLC ADR was acquired by Merck (MRK) on October 7, 2025. Shareholders received $107.00 per American Depositary Share in cash for each share. VRNA stock stopped trading on the Nasdaq, with a final close of $106.91 on October 6, 2025.
What did Verona Pharma PLC ADR shareholders receive?
Each VRNA share was converted into $107.00 per American Depositary Share in cash. The deal was valued at about $10 billion.
Is VRNA stock still trading?
No. VRNA was delisted from the Nasdaq on October 7, 2025 and no longer trades on a U.S. exchange. Former Verona Pharma PLC ADR shareholders received Merck (MRK) shares.
What was the last price of VRNA stock?
VRNA closed at $106.91 on its final trading day, October 6, 2025, for a market value of about $9.09B.
What were Verona Pharma PLC ADR's revenue and earnings in its last full fiscal year?
Verona Pharma PLC ADR reported revenue of $33.77M and net income of -$138.5M in fiscal 2024, its last full year as a public company.
When did Verona Pharma PLC ADR go public?
Verona Pharma PLC ADR stock began trading on April 27, 2017.